Outcomes out to 12 months after sequential use of high‐dose tofacitinib following infliximab in acute severe ulcerative colitis

• Published in: Internal medicine journal 2023-08, Vol.53 (8), p.1497-1500
• Main Authors: Eqbal, Ali, Hilley, Patrick, Choy, Matthew, Srinivasan, Ashish, Cruz, Peter
• Format: Article
• Language: English
• Subjects: acute severe colitis; Inflammatory bowel disease; Infliximab; Monoclonal antibodies; Morbidity; Patients; sequential therapy; Steroids; Thromboembolism; tofacitinib; Tumor necrosis factor-α; Ulcerative colitis
• ISSN: 1444-0903; 1445-5994
• DOI: 10.1111/imj.16192

Acute severe colitis (ASUC) remains a significant cause of morbidity in up to 25% of patients with ulcerative colitis during their disease course. We present the outcomes out to 12 months following the use of high‐dose tofacitinib, 10 mg three times daily (TDS), in patients with steroid and infliximab refractory ASUC. A total of 11 patients with ASUC who were treated with high‐dose tofacitinib after failing sequential infliximab therapy between 2019 and 2021 were identified at an Australian tertiary centre. Ten of 11 patients demonstrated clinical and biochemical response to treatment during admission. Two of 11 patients required colectomy, one during the index admission and the other during re‐admission 10 days after the index presentation. Nine of the initial responders had a median Mayo score of 1 (IQR 0–4) at both 6 and 12 months, and all remained colectomy‐free out to 12 months. Neither venous thromboembolic events nor major infective complications were observed. Tofacitinib may be a safe and effective induction and maintenance agent in the treatment of steroid and infliximab refractory ASUC. Prospective studies with long‐term follow‐up are required to explore the use of tofacitinib in ASUC before it can be routinely recommended as salvage therapy.